US · CRBU
Caribou Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Berkeley, CA 94710
- Website
- cariboubio.com
Price · as of 2024-12-31
$1.87
Market cap 177.59M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $25.48 | +1,262.57% |
| Intrinsic Value(DCF) | $0.82 | -56.15% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $98.70 | +5,177.81% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $9.19 | $29.04 | $4.92 | $0.88 | $14.77 |
| 2022 | $5.18 | $23.94 | $2.58 | $0.00 | $0.00 |
| 2023 | $7.42 | $39.16 | $1,251.93 | $0.00 | $0.00 |
| 2024 | $1.16 | $25.48 | $0.59 | $0.00 | $98.69 |
AI valuation
Our deep-learning model estimates Caribou Biosciences, Inc.'s (CRBU) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $25.48
- Current price
- $1.87
- AI upside
- +1,262.57%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.82
-56.15% upside
Graham-Dodd
—
— upside
Graham Formula
$98.70
+5,177.81% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CRBU | Caribou Biosciences, Inc. | $1.87 | 177.59M | +1,263% | -56% | — | +5,178% | -0.70 | 0.41 | 10.48 | 0.48 | -3.59 | 0.41 | 60.71% | -1667.16% | -1491.95% | -47.99% | -243.96% | -40.00% | 0.10 | — | 7.16 | 6.94 | -0.06 | 1957.00% | -7101.00% | 3794.00% | -138.12% | -4.51 | -211.89% | 0.00% | 0.00% | 0.00% | 0.47 | 0.54 | -7.83 | -1.96 |
| AARD | Aardvark Therapeutics, In… | $12.49 | 271.95M | — | — | — | — | -6.35 | -2.39 | — | -2.56 | -3.45 | -2.39 | 0.00% | — | — | 46.03% | 26.47% | -46.77% | -0.01 | — | 15.05 | 14.95 | 2.69 | 18393.00% | — | 21243.00% | -13.91% | -3.67 | 21.14% | 0.00% | 0.00% | 39.22% | -2.54 | -3.18 | — | -0.36 |
| ALLO | Allogene Therapeutics, In… | $2.78 | 624.75M | +924% | -60% | — | +3,007% | -1.65 | 1.01 | 19304.10 | -0.92 | — | 1.01 | 100.00% | -1241813.64% | -1170863.64% | -55.13% | -144.12% | -43.24% | 0.21 | -1509.39 | 8.54 | 8.29 | -0.06 | -3684.00% | -7684.00% | -1599.00% | -47.33% | -5.64 | -106.03% | 0.00% | 0.00% | 0.00% | -0.82 | -1.11 | 10135.01 | -3.69 |
| ENTA | Enanta Pharmaceuticals, I… | $14.30 | 332M | +189% | -59% | — | — | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -2993.00% | -342.00% | -6674.00% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| FHTX | Foghorn Therapeutics Inc. | $5.68 | 332.74M | +360% | -68% | — | +572% | -2.86 | -5.45 | 10.98 | -0.43 | — | -5.45 | 100.00% | -454.31% | -383.24% | 141.17% | 39.62% | -30.40% | -0.82 | — | 3.73 | 3.64 | 0.19 | -3248.00% | -3383.00% | -1510.00% | -40.83% | -1.50 | 39.09% | 0.00% | 0.00% | 0.00% | -0.40 | -0.41 | 1.84 | -2.64 |
| HUMA | Humacyte, Inc. | $1.12 | 159.24M | — | — | — | — | -2.46 | -6.95 | — | -2.55 | -13.86 | -6.95 | 0.00% | — | — | 760.17% | 252.76% | -111.77% | -0.31 | -12.33 | 2.40 | 2.25 | 0.21 | 1776.00% | — | 3190.00% | -27.23% | -4.92 | 220.27% | 0.00% | 0.00% | 1.48% | -2.95 | -3.39 | — | -8.31 |
| IVA | Inventiva S.A. | $6.49 | 337.36M | +349% | -81% | — | +2,278% | -0.75 | -1.30 | 15.02 | -0.58 | -1.64 | -1.29 | 100.00% | -1060.64% | -2002.74% | 265.67% | 114.26% | -195.42% | -0.51 | -8.01 | 0.92 | 0.90 | 0.25 | 4568.00% | -4737.00% | 500.00% | -62.45% | -0.71 | 101.03% | 0.00% | 0.00% | 38.23% | -0.98 | -1.11 | 10.43 | -4.52 |
| OBIO | Orchestra BioMed Holdings… | $4.38 | 247.32M | +415% | -61% | — | — | -2.55 | 4.73 | 59.04 | -1.65 | -20.99 | 4.73 | 92.27% | -2437.49% | -2313.27% | -120.84% | 365.45% | -71.21% | 0.50 | — | 4.27 | 4.13 | 0.09 | 1216.00% | -442.00% | 1005.00% | -32.65% | -3.12 | 288.99% | 0.00% | 0.00% | 0.00% | -1.64 | -2.07 | 39.98 | -5.45 |
| PRLD | Prelude Therapeutics Inco… | $2.76 | 210M | — | — | — | — | -0.44 | 0.42 | 7.97 | 0.43 | — | 0.42 | 100.00% | -1995.91% | -1816.76% | -69.01% | -756.99% | -56.12% | 0.14 | — | 5.30 | 5.21 | -0.04 | -1683.00% | — | -626.00% | -185.78% | -4.01 | -561.60% | 0.00% | 0.00% | 0.00% | 0.43 | 0.58 | -8.54 | -5.73 |
| PYXS | Pyxis Oncology, Inc. | $1.47 | 91.53M | — | — | — | — | -0.88 | 0.56 | 4.20 | 0.59 | — | 0.57 | 97.06% | -554.07% | -478.95% | -62.75% | -416.82% | -46.74% | 0.17 | — | 7.49 | 7.18 | -0.01 | -2865.00% | — | -2522.00% | -85.42% | -3.26 | -277.36% | 0.00% | 0.00% | 16.14% | 0.44 | 0.67 | -2.41 | -3.02 |
| TNYA | Tenaya Therapeutics, Inc. | $0.56 | 93.6M | — | — | — | — | -0.35 | 0.42 | — | 0.09 | — | 0.42 | 0.00% | — | — | -95.69% | -251.45% | -76.52% | 0.15 | — | 4.22 | 3.85 | -0.09 | -2202.00% | — | -1141.00% | -237.15% | -5.67 | -198.49% | 0.00% | 0.00% | 0.00% | 0.08 | 0.10 | — | -7.83 |
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
- CEO
- Rachel E. Haurwitz
- Employees
- 147
- Beta
- 2.61
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.82 ÷ $1.87) − 1 = -56.15% (DCF, example).